Alignment Healthcare Insider Sells $1.3 Million in Stock With Shares Up 78% This Past Year

On Dec. 29 Alignment Healthcare CIO Robert L. Scavo executed an open-market sale of 69,541 shares for roughly $1.3 million, reducing his direct holdings from 572,555 to 503,014 shares (≈12.15% of his direct stake); the Form 4 indicates the sale was non‑discretionary to cover tax withholding on vesting performance share units. The company reported a strong operating quarter with Q3 revenue of $993.7 million (+43.5% YoY), membership up ~26%, $32.4 million of adjusted EBITDA and raised full‑year guidance; TTM revenue is $3.64 billion with a TTM net loss of $20.81 million, and the stock has rallied roughly 78% over the past year.

Analysis

Market structure: The CIO sale was tax-driven and small relative to public float, so immediate supply impact is minimal; ALHC’s +78% Y/Y move and Q3 membership +26% suggest demand is momentum-driven and concentrated in growth-oriented MA/tech names. Winners are growth-oriented Medicare Advantage specialists (ALHC, selected regional peers) and tech-enabled care platforms; losers are commodity PBMs and non-MA insurers with weaker Medicare distribution. Cross-asset: negligible credit/FX impact, slight lift to small-cap healthcare ETFs and muted option-volatility compression ahead of earnings.

Risk assessment: Tail risks include adverse CMS rate decisions, COVID-style utilization swings, or provider contracting disputes that can create a 10–20% EPS shock; regulatory action within 90–180 days could be binary. Near-term (days/weeks): stock moves on headlines and insider filings; short-term (1–3 months): earnings, AEP/enrollment updates matter; long-term (1–3 years): margin trajectory driven by medical-loss-ratio and network scale. Hidden dependency: scaling membership quickly can raise short-term medical costs (MLR) before benefits of fixed-cost leverage kick in.

Trade implications: Tactical long ALHC exposure size 2–3% of NAV between $17.5–$21 with stop-loss ~12% below entry and take-profit +30–40% within 6–12 months; pair trade long ALHC / short HUM (dollar-neutral) to isolate MA growth vs. scale risk. Options: implement defined-risk 12-month call spread (buy ALHC Jan-2027 20C, sell Jan-2027 30C) sized to 0.5–1% NAV, and buy 6–12 month 15 puts as tail hedge if position >2%.

Contrarian angles: Market is understating regulatory/regional-network risk while over-crediting membership growth—insider sale pattern (12% of direct holdings) is consistent with tax liquidity, not loss of confidence. Historical parallels (rapid MA growth followed by MLR pressure at scale) suggest build defensive hedges; if Q4 membership growth falls to <10% QoQ or adjusted EBITDA margin dips below 3% on next report, treat as trigger to reduce exposure by half.

Key Decisions for Investors

• Establish a 2–3% long position in ALHC (ticker: ALHC) via purchases in the $17.5–$21 band; set a hard stop-loss ~12% below entry and plan to take profits at +30–40% within 6–12 months, reassess after next quarterly results.
• Implement a defined-risk options bull call spread: buy ALHC Jan-2027 20C and sell Jan-2027 30C (or nearest strikes) sized to 0.5–1% of NAV to cap downside while retaining upside through next 12 months.
• Open a dollar-neutral pair: long ALHC / short HUM (Humana) equal-dollar to express growth-over-scale exposure; target spread improvement of 10–15% within 3–9 months and rebalance on CMS or earnings surprises.
• If any ALHC position exceeds 2% NAV, purchase 6–12 month ALHC 15 puts as tail protection or cap sector exposure to 3% of portfolio; reduce ALHC exposure by 50% if Q4 membership growth <10% QoQ or adjusted EBITDA margin <3% on next report.